Galderma study shows early promise of lamellar ichthyosis treatment

Galderma has announced new early-stage clinical trial data that demonstrates the potential benefits of its new treatment for the rare disease lamellar ichthyosis.

Trifarotene is a first-in-class molecule that is in development for use against a range of dermatological conditions. A cream formulation has been developed by Galderma to adapt to the disease condition.

In a phase I study, the cream was shown to be safe and well-tolerated in the treatment of lamellar ichthyosis, a debilitating orphan disease resulting in the formation of scales covering the skin.

The condition is known to significantly affect patients' quality of life, creating a great need of effective, safe and specific treatments.

Dr Thibaud Portal, vice-president of Galderma's prescription business, said: "We are dedicated to meeting the needs of all patients with skin diseases over the course of their lives, and trifarotene has been designed to meet the safety profile that patients with lamellar ichtyosis need."

Galderma is also exploring the benefits of trifarotene in the treatment of other rare skin diseases, such as cutaneous T-cell lymphoma and Gorlin syndrome.